Surveillance of molecular markers of Plasmodium falciparum artemisinin resistance (kelch13 mutations) in Papua New Guinea between 2016 and 2018.

Antimalarial drug resistance Artemisinin resistance Malaria control Plasmodium falciparum Surveillance kelch13 mutations

Journal

International journal for parasitology. Drugs and drug resistance
ISSN: 2211-3207
Titre abrégé: Int J Parasitol Drugs Drug Resist
Pays: Netherlands
ID NLM: 101576715

Informations de publication

Date de publication:
08 2021
Historique:
received: 07 04 2021
revised: 22 06 2021
accepted: 25 06 2021
pubmed: 17 7 2021
medline: 12 10 2021
entrez: 16 7 2021
Statut: ppublish

Résumé

Plasmodium falciparum resistance to artemisinin-based combination therapy (ACT) is a global threat to malaria control and elimination efforts. Mutations in the P. falciparum kelch13 gene (Pfk13) that are associated with delayed parasite clearance have emerged on the Thai-Cambodian border since 2008. There is growing evidence of widespread Pfk13 mutations throughout South-East Asia and they have independently emerged in other endemic regions. In Papua New Guinea (PNG), Pfk13 "C580Y" mutant parasites with reduced in vitro sensitivity to artemisinin have been isolated in Wewak, a port town in East Sepik Province. However, the extent of any local spread of these mutant parasites in other parts of PNG is unknown. We investigated the prevalence of Pfk13 mutations in multiple malaria-endemic regions of PNG. P. falciparum isolates (n = 1152) collected between 2016 and 2018 and assessed for Pfk13 variation by sequencing. Of 663 high quality Pfk13 sequences a total of five variants were identified. They included C580Y, a mutation at a previously documented polymorphic locus: N499K, and three previously undescribed mutations: R471C, K586E and Y635C. All variants were found in single isolates, indicating that these Pfk13 mutations were rare in the areas surveyed. Notably, C580Y was absent from Maprik district, which neighbours Wewak where C580Y mutant parasites were previously identified. The single C580Y isolate was found in the port town of Lae, Morobe Province, a potential entry site for the importation of drug resistant parasites into PNG. Although sample size in this location was small (n = 5), our identification of a C580Y mutant in this second location is concerning, highlighting the urgent need for further surveillance in Lae. Other Pfk13 mutants were rare in PNG between 2016 and 2018. Continued surveillance for molecular markers of drug resistance is critically important to inform malaria control in PNG.

Identifiants

pubmed: 34271323
pii: S2211-3207(21)00031-2
doi: 10.1016/j.ijpddr.2021.06.004
pmc: PMC8286961
pii:
doi:

Substances chimiques

Antimalarials 0
Artemisinins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

188-193

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Dulcie Lautu-Gumal (D)

Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia; Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea; Life Sciences Discipline, Burnet Institute, Melbourne, Victoria, Australia. Electronic address: dulcie.lautu@burnet.edu.au.

Zahra Razook (Z)

Life Sciences Discipline, Burnet Institute, Melbourne, Victoria, Australia; Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, Victoria, Australia.

Tamarah Koleala (T)

Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea.

Elma Nate (E)

Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea.

Samuel McEwen (S)

Life Sciences Discipline, Burnet Institute, Melbourne, Victoria, Australia.

Diana Timbi (D)

Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea.

Manuel W Hetzel (MW)

Health Interventions Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.

Evelyn Lavu (E)

Papua New Guinea Central Public Health Laboratories, Port Moresby, National Capital District, Papua New Guinea.

Nakapi Tefuarani (N)

School of Medicine & Health Sciences, University of Papua New Guinea, Port Moresby, National Capital District, Papua New Guinea.

Leo Makita (L)

Papua New Guinea National Department of Health, Port Moresby, National Capital District, Papua New Guinea.

James Kazura (J)

Centre for Global Health Diseases, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Ivo Mueller (I)

Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia; Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.

William Pomat (W)

Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea.

Moses Laman (M)

Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea.

Leanne J Robinson (LJ)

Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia; Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Madang Province, Papua New Guinea; Life Sciences Discipline, Burnet Institute, Melbourne, Victoria, Australia; School of Preventative Medicine and Public Health, Monash University, Melbourne, Victoria, Australia.

Alyssa E Barry (AE)

Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia; Life Sciences Discipline, Burnet Institute, Melbourne, Victoria, Australia; Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, Victoria, Australia.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female
Humans Receptors, Antigen, T-Cell Proto-Oncogene Proteins p21(ras) Pancreatic Neoplasms T-Lymphocytes

Classifications MeSH